期刊文献+

肾苏Ⅲ修复损伤足细胞改善血管通透性的机制研究

Mechanism of Shensu Ⅲ Repairing Podocytes to Improve Vascular Permeability
下载PDF
导出
摘要 目的:通过观察中药复方肾苏Ⅲ调控血管生成素对损伤足细胞的修复作用,阐明其防治作用的关节调节点及可能的机制。方法:采用Real-time PCR、Western Blot检测方法,对肾苏Ⅲ干预前后足细胞中血管生成素(Angiopoietin,Ang)-1、Ang-2、Tie-2 mRNA进行检测。结果:48 h后肾苏Ⅲ治疗组与模型组比较,Ang-1、Ang-2 mRNA、蛋白表达量显著增加;Tie-2蛋白表达量明显减少。结论:肾苏Ⅲ通过调节Ang-1、Ang-2/Tie-2mRNA及蛋白表达量,对不成熟的血管网进行重塑,增强管状结构与附近组织及细胞的黏附,维持血管的完整性,促进和维持血管成熟稳定、降低血管通透性。 Objective:To observe the effect of Shensu Ⅲ,which is a traditional Chinese drug compound,on the repairing of the injured podocytes and to elucidate the possible mechanism of its regulating action.Methods:Angiopoietin(Ang)-1,Ang-2 and Tie-2 mRNA were detected by applying the methods of Real-time PCR and Western Blot.Results:48 hours later,compared with that of the model group,the expression of Ang-1 and Ang-2 mRNA and protein increased significantly and the expression of Tie-2 protein significantly decreased in the Shensu Ⅲ treatment group.Conclusion:Shensu Ⅲ can modulate the expression of Ang-1,Ang-2/Tie-2 mRNA and protein,remodel the immature vascular network,enhance the adhesion between tubular structure and adjacent tissues and cells,and maintain vascular integrity,to promote and maintain vascular maturation and stability and to reduce the vascular permeability.
出处 《中医学报》 CAS 2016年第11期1746-1749,共4页 Acta Chinese Medicine
基金 国家自然科学基金(81173242)
关键词 肾苏Ⅲ 血管内皮生长因子 ANG-1 ANG-2 TIE-2 足细胞 Shensu Ⅲ vascular endothelial growth factor Podocytes
  • 相关文献

参考文献1

二级参考文献14

  • 1Flyvbjerg A.Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease.Diabetologia,2000,43:1205-1223.
  • 2Yancopoulos GD,Davis S,Gale NW,et al.Vascular-specific growth factors and blood vessel formation.Nature,2000,407(6801):242-248.
  • 3Abdulmalek K,Ashur F,Ezer N,et al.Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats.Am J Physiol Lung Cell Mol Physiol,2001,281:L582-L590.
  • 4Yamamoto Y,Maeshima Y,Kitayama H,et al.Tumstatin peptide,an inhibitor of angiogenesis,prevents glomerular hypertrophy in the early stage of diabetic nephropathy.Diabetes,2004,53:1831-1840.
  • 5Osterby R,Asplund J,Bangstad HJ,et al.Neovascularization at the vascular pole region in diabetic glomerulopathy.Nephrol Dial Transplant,1999,14:348-352.
  • 6Satchell SC,Mathieson PW.Angiopoietins:microvascular modulators with potential roles in glomerular pathophysiology.J Nephrol,2003,16:168-178.
  • 7Padro T,Ruiz S,Bieker R,et al.Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.Blood,2000,95:2637-2644.
  • 8Khamaisi M,Schrijvers BF,De Vriese AS,et al.The emerging role of VEGF in diabetic kidney disease.Nephrol Dial Transplant,2003,18:1427-1430.
  • 9Thurston C,Suri C,Smith K,et al.Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1.Science,1999,286(5449):2511-2514.
  • 10Enholm B,Paavonen K,Ristimaki A,et al.Comparison of VEGF,VEGF-B,VEGF-C and Ang-1 mRNA regulation by serum,growth factors,oncoproteins and hypoxia.Oncogene,1997,14:2475 -2483.

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部